PSMG1 and prostate cancer: While the present work shows that miR-484 is a candidate negative prognostic biomarker in prostate cancer likely by targeting PSMG1 and modulating cell mobility, its conclusions are based on analyses from patient samples and in vitro experiments using cancer cell lines, which have limitations.